On 26 April 2012, orphan designation (EU/3/12/988) was granted by the European Commission to Biological Consulting Europe Ltd, United Kingdom, for the treatment of Duchenne muscular dystrophy.
- What is Duchenne muscular dystrophy?
Duchenne muscular dystrophy (DMD) is a genetic disease that gradually causes weakness and atrophy (wasting) of the muscles. It mainly affects boys, and symptoms usually start before the age of six years. The muscle weakness usually starts in the hips and legs, before reaching the chest, arms, and sometimes the heart. Patients with DMD lack normal dystrophin, a protein found in muscles. Because this protein helps to strengthen and protect muscles from injury as muscles contract and relax, in patients with DMD the muscles become weak and eventually stop working.
DMD causes long-term disability and is life threatening because of its effects on the heart and the respiratory muscles (muscles that are used to breathe). The disease usually leads to death in adolescence.
- What is the estimated number of patients affected by the condition?
At the time of designation, DMD affected approximately 0.4 in 10,000 people in the European Union (EU)*. This is equivalent to a total of around 20,000 people, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).
*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 27), Norway, Iceland and Liechtenstein. This represents a population of 506,300,000 (Eurostat 2011).
- What treatments are available?
At the time of submission of the application for orphan designation, no satisfactory method had been authorised in the European Union for treatment of the condition. Treatment of patients with Duchenne muscular dystrophy primarily involves physiotherapy and other supportive treatments.
- How is this medicine expected to work?
Because patients with DMD lack dystrophin, muscles get damaged with repetitive contractions, causing inflammation. This results in muscle fibrosis, where the damaged muscle cells accumulate too much collagen-rich, fibrous tissue that contributes to the progressive muscle weakness in DMD patients.
Halofuginone hydrobromide is expected to reduce muscle fibrosis by blocking the effects of ‘transforming growth factor beta’ (TGF-beta), a protein found in high levels in muscle and plasma of DMD patients, which is involved in the production of excess collagen. By reducing the production of excess collagen, this medicine is expected to reduce the fibrosis and improve muscular function.
In addition, halofuginone hydrobromide is also expected to have anti-inflammatory effects and to increase muscle regeneration.
- What is the stage of development of this medicine?
At the time of submission of the application for orphan designation, the evaluation of the effects of halofuginone hydrobromide in experimental models was ongoing.
At the time of submission of the application for orphan designation, no clinical trials with the medicine in patients with DMD had been started.
At the time of submission, the medicine was not authorised anywhere in the EU for treatment of DMD. Orphan designation has been granted in the United States of America for this condition.
In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 8 March 2012 recommending the granting of this designation.
- Opinions on orphan medicinal product designations are based on the following three criteria:
- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.
Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.
|Name||Language||First published||Last updated|
|EU/3/12/988: Public summary of opinion on orphan designation: Halofuginone hydrobromide for the treatment of Duchenne muscular dystrophy||(English only)||18/06/2012|
|Active substance||Halofuginone hydrobromide|
|Disease/condition||Treatment of Duchenne muscular dystrophy|
|Date of decision||26/04/2012|
|Orphan decision number||EU/3/12/988|
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor’s contact details:
Biological Consulting Europe Ltd
Logan Building, Roslin BioCentre
Telephone: +44 131 440 64 80
Telefax: Fax +44 131 440 64 86
For contact details of patients’ organisations whose activities are targeted at rare diseases see:
- Orphanet, a database containing information on rare diseases which includes a directory of patients’ organisations registered in Europe.
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.